Prelude Therapeutics Incorporated
PRLD
$1.27
$0.032.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.32M | -127.83M | -127.17M | -131.52M | -129.85M |
| Total Depreciation and Amortization | 1.76M | 1.78M | 1.77M | 1.61M | 1.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.99M | 18.17M | 18.30M | 20.54M | 20.60M |
| Change in Net Operating Assets | -2.78M | 2.55M | 4.22M | 3.65M | 3.65M |
| Cash from Operations | -108.35M | -105.33M | -102.89M | -105.72M | -104.11M |
| Capital Expenditure | -183.00K | -522.00K | -764.00K | -1.84M | -2.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.74M | 121.68M | 90.96M | 77.65M | 82.49M |
| Cash from Investing | 106.56M | 121.16M | 90.19M | 75.81M | 80.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -507.00K | -550.00K | -395.00K | -244.00K | -96.00K |
| Issuance of Common Stock | 272.00K | 437.00K | 439.00K | 25.55M | 25.60M |
| Repurchase of Common Stock | -27.00K | -43.00K | -54.00K | -48.00K | -51.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.00K | -110.00K | -110.00K | -110.00K | -84.00K |
| Cash from Financing | -288.00K | -266.00K | -120.00K | 25.15M | 25.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.08M | 15.56M | -12.82M | -4.76M | 1.38M |